Titulo:

.

Guardado en:

0121-5426

2538-9513

25

2016-11-22

145

156

Darío Londoño - 2013

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.

info:eu-repo/semantics/openAccess

http://purl.org/coar/access_right/c_abf2

id metarevistapublica_asoneumocito_revistacolombianadeneumologia_28_article_548
record_format ojs
spelling Introduction: pulmonary arterial hypertension is an uncommon condition, whose morbidity and mortality are high. Its diagnosis is highly specialized and very costly. The same holds true for its treatment, follow-up, absences from work, and hospitalizations for its cause. In Colombia, the costs associated with the diagnosis and treatment of this condition, which are essential for Methods: Direct costs: the diagnostic algorithm for pulmonary arterial hypertension of the European Respiratory Society (ERS) was applied to an hypothetic cohort of one hundred patients with pulmonary hypertension. A value was assigned to each procedure in accordance with the national tariff manual. Diagnosis was divided into an initial phase, focusing on ruling out groups I, II, IV of pulmonary hypertension, and a second phase, focusing on hemodynamic diagnosis, exercise capabiltiy, and type. A delphi panel indicated therapy according to the functional class, the follow-up procedures, and their frequency. Indirect costs: these were established by interviewing 35 patients with pulmonary arterial hypertension about lost working days and disabilities. Total costs are equal to the sum of direct and indirect costs. All costs are presented in US dollars (1 US dollar = 1.900 Colombian pesos for the year 2010). Results: Direct costs: during the first phase of diagnosis, an investment of US $23,874.90 was done for 100 patients, which represents an investment of US $238,749 per patient. For the second phase, the investment is close to US $14,854.57, corresponding to $742,7 per patient. In patients with functional classes II and III, the total cost for 100 patients is US $9,128,933.46, both for inpatients and outpatients. In functional class IV patients, the total cost of managing 100 individuals is US $35,128,260.2, which represents an average cost of US $351,282.6 per patient. Costs are increased by 384,6% in class IV patients in comparison with class II-III patients. Indirect costs: 31% of surveyed patients had to take leaves from work during the last year (an average of 58 days), and 28,6% required hospitalization. Taking into account that the minimum legal monthly salary in Colombia is US $279, the average monthly income of surveyed patients was US $804 (daily income of US $26,8). The cost of absences from work of the eleven subjects was US $17,098.4. Since insurance companies in Colombia cover only 70% of income from salaries, it can be said that the subjects will have to invest 30% of their monthly income. Conclusions: the direct costs of diagnosing and treating pulmonary arterial hypertension are very high, even when adequate guidelines are used. These costs increase as the functional class worsens. This reminds us of the importance of early diagnosis, not only for improving survival, but also for potentially reducing costs. The direct cost payed by patients with pulmonary arterial hypertension in Colombia had a very high impact on their monthly income, which could reduce their compliance with treatment.
Londoño, Darío
Villaquirán, Claudio
Dueñas, Rubén
Gómez, Efraín
Coral, Paola
Pulmonary hypertension
Direc costs
Indirect costs
Hipertensión pulmonar
Costos directos
Costos indirectos
25
3
Artículo de revista
Journal article
2016-11-22T21:53:55Z
2016-11-22T21:53:55Z
2016-11-22
application/pdf
Asociación Colombiana de Neumología y Cirugía de Tórax
Revista Colombiana de Neumología
0121-5426
2538-9513
https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/548
10.30789/rcneumologia.v25.n3.2013.548
https://doi.org/10.30789/rcneumologia.v25.n3.2013.548
spa
https://creativecommons.org/licenses/by-nc-sa/4.0/
Darío Londoño - 2013
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
145
156
https://revistas.asoneumocito.org/index.php/rcneumologia/article/download/548/466
info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
http://purl.org/coar/resource_type/c_2df8fbb1
http://purl.org/redcol/resource_type/ART
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/version/c_970fb48d4fbd8a85
info:eu-repo/semantics/openAccess
http://purl.org/coar/access_right/c_abf2
Text
Publication
institution ASOCIACION COLOMBIANA DE NEUMOLOGIA Y CIRUGIA DE TORAX
thumbnail https://nuevo.metarevistas.org/ASOCIACIONCOLOMBIANADENEUMOLOGIAYCIRUGIADETORAX/logo.png
country_str Colombia
collection Revista Colombiana de Neumología
description_eng Introduction: pulmonary arterial hypertension is an uncommon condition, whose morbidity and mortality are high. Its diagnosis is highly specialized and very costly. The same holds true for its treatment, follow-up, absences from work, and hospitalizations for its cause. In Colombia, the costs associated with the diagnosis and treatment of this condition, which are essential for Methods: Direct costs: the diagnostic algorithm for pulmonary arterial hypertension of the European Respiratory Society (ERS) was applied to an hypothetic cohort of one hundred patients with pulmonary hypertension. A value was assigned to each procedure in accordance with the national tariff manual. Diagnosis was divided into an initial phase, focusing on ruling out groups I, II, IV of pulmonary hypertension, and a second phase, focusing on hemodynamic diagnosis, exercise capabiltiy, and type. A delphi panel indicated therapy according to the functional class, the follow-up procedures, and their frequency. Indirect costs: these were established by interviewing 35 patients with pulmonary arterial hypertension about lost working days and disabilities. Total costs are equal to the sum of direct and indirect costs. All costs are presented in US dollars (1 US dollar = 1.900 Colombian pesos for the year 2010). Results: Direct costs: during the first phase of diagnosis, an investment of US $23,874.90 was done for 100 patients, which represents an investment of US $238,749 per patient. For the second phase, the investment is close to US $14,854.57, corresponding to $742,7 per patient. In patients with functional classes II and III, the total cost for 100 patients is US $9,128,933.46, both for inpatients and outpatients. In functional class IV patients, the total cost of managing 100 individuals is US $35,128,260.2, which represents an average cost of US $351,282.6 per patient. Costs are increased by 384,6% in class IV patients in comparison with class II-III patients. Indirect costs: 31% of surveyed patients had to take leaves from work during the last year (an average of 58 days), and 28,6% required hospitalization. Taking into account that the minimum legal monthly salary in Colombia is US $279, the average monthly income of surveyed patients was US $804 (daily income of US $26,8). The cost of absences from work of the eleven subjects was US $17,098.4. Since insurance companies in Colombia cover only 70% of income from salaries, it can be said that the subjects will have to invest 30% of their monthly income. Conclusions: the direct costs of diagnosing and treating pulmonary arterial hypertension are very high, even when adequate guidelines are used. These costs increase as the functional class worsens. This reminds us of the importance of early diagnosis, not only for improving survival, but also for potentially reducing costs. The direct cost payed by patients with pulmonary arterial hypertension in Colombia had a very high impact on their monthly income, which could reduce their compliance with treatment.
author Londoño, Darío
Villaquirán, Claudio
Dueñas, Rubén
Gómez, Efraín
Coral, Paola
spellingShingle Londoño, Darío
Villaquirán, Claudio
Dueñas, Rubén
Gómez, Efraín
Coral, Paola
Pulmonary hypertension
Direc costs
Indirect costs
Hipertensión pulmonar
Costos directos
Costos indirectos
author_facet Londoño, Darío
Villaquirán, Claudio
Dueñas, Rubén
Gómez, Efraín
Coral, Paola
topic Pulmonary hypertension
Direc costs
Indirect costs
Hipertensión pulmonar
Costos directos
Costos indirectos
topic_facet Pulmonary hypertension
Direc costs
Indirect costs
Hipertensión pulmonar
Costos directos
Costos indirectos
topicspa_str_mv Hipertensión pulmonar
Costos directos
Costos indirectos
citationvolume 25
citationissue 3
publisher Asociación Colombiana de Neumología y Cirugía de Tórax
ispartofjournal Revista Colombiana de Neumología
source https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/548
language spa
format Article
rights https://creativecommons.org/licenses/by-nc-sa/4.0/
Darío Londoño - 2013
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
info:eu-repo/semantics/openAccess
http://purl.org/coar/access_right/c_abf2
type_driver info:eu-repo/semantics/article
type_coar http://purl.org/coar/resource_type/c_6501
type_version info:eu-repo/semantics/publishedVersion
type_coarversion http://purl.org/coar/version/c_970fb48d4fbd8a85
type_content Text
publishDate 2016-11-22
date_accessioned 2016-11-22T21:53:55Z
date_available 2016-11-22T21:53:55Z
url https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/548
url_doi https://doi.org/10.30789/rcneumologia.v25.n3.2013.548
issn 0121-5426
eissn 2538-9513
doi 10.30789/rcneumologia.v25.n3.2013.548
citationstartpage 145
citationendpage 156
url2_str_mv https://revistas.asoneumocito.org/index.php/rcneumologia/article/download/548/466
_version_ 1811200726109519872